462 related articles for article (PubMed ID: 31841768)
1. Towards the overcoming of anticancer drug resistance mediated by p53 mutations.
Cao X; Hou J; An Q; Assaraf YG; Wang X
Drug Resist Updat; 2020 Mar; 49():100671. PubMed ID: 31841768
[TBL] [Abstract][Full Text] [Related]
2. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
[TBL] [Abstract][Full Text] [Related]
3. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
Yang L; Zhou Y; Li Y; Zhou J; Wu Y; Cui Y; Yang G; Hong Y
Cancer Lett; 2015 Feb; 357(2):520-6. PubMed ID: 25499080
[TBL] [Abstract][Full Text] [Related]
4. How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance.
Stiewe T; Haran TE
Drug Resist Updat; 2018 May; 38():27-43. PubMed ID: 29857816
[TBL] [Abstract][Full Text] [Related]
5. Taxanes in cancer treatment: Activity, chemoresistance and its overcoming.
Mosca L; Ilari A; Fazi F; Assaraf YG; Colotti G
Drug Resist Updat; 2021 Jan; 54():100742. PubMed ID: 33429249
[TBL] [Abstract][Full Text] [Related]
6. Surmounting cancer drug resistance: New insights from the perspective of N
Li B; Jiang J; Assaraf YG; Xiao H; Chen ZS; Huang C
Drug Resist Updat; 2020 Dec; 53():100720. PubMed ID: 32892147
[TBL] [Abstract][Full Text] [Related]
7. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
[TBL] [Abstract][Full Text] [Related]
8. The role of p53 in cancer drug resistance and targeted chemotherapy.
Hientz K; Mohr A; Bhakta-Guha D; Efferth T
Oncotarget; 2017 Jan; 8(5):8921-8946. PubMed ID: 27888811
[TBL] [Abstract][Full Text] [Related]
9. Mutant p53 promotes RCP-dependent chemoresistance coinciding with increased delivery of P-glycoprotein to the plasma membrane.
Phatak V; von Grabowiecki Y; Janus J; Officer L; Behan C; Aschauer L; Pinon L; Mackay H; Zanivan S; Norman JC; Kelly M; Le Quesne J; Muller PAJ
Cell Death Dis; 2021 Feb; 12(2):207. PubMed ID: 33627632
[TBL] [Abstract][Full Text] [Related]
10. Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach.
Taylor S; Spugnini EP; Assaraf YG; Azzarito T; Rauch C; Fais S
Drug Resist Updat; 2015 Nov; 23():69-78. PubMed ID: 26341193
[TBL] [Abstract][Full Text] [Related]
11. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic enzyme mutations as mediators of anti-cancer drug resistance.
Chen S; Zhao Y; Liu S; Zhang J; Assaraf YG; Cui W; Wang L
Drug Resist Updat; 2022 Mar; 61():100821. PubMed ID: 35219075
[TBL] [Abstract][Full Text] [Related]
13. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
Shapira A; Livney YD; Broxterman HJ; Assaraf YG
Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
[TBL] [Abstract][Full Text] [Related]
14. Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function.
Gao L; Wu ZX; Assaraf YG; Chen ZS; Wang L
Drug Resist Updat; 2021 Jul; 57():100770. PubMed ID: 34175687
[TBL] [Abstract][Full Text] [Related]
15. Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin.
Wiegering A; Matthes N; Mühling B; Koospal M; Quenzer A; Peter S; Germer CT; Linnebacher M; Otto C
Neoplasia; 2017 Apr; 19(4):301-309. PubMed ID: 28284059
[TBL] [Abstract][Full Text] [Related]
16. Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells.
Masciarelli S; Fontemaggi G; Di Agostino S; Donzelli S; Carcarino E; Strano S; Blandino G
Oncogene; 2014 Mar; 33(12):1601-8. PubMed ID: 23584479
[TBL] [Abstract][Full Text] [Related]
17. Mutant p53 Gain of Function and Chemoresistance: The Role of Mutant p53 in Response to Clinical Chemotherapy.
He C; Li L; Guan X; Xiong L; Miao X
Chemotherapy; 2017; 62(1):43-53. PubMed ID: 27322648
[TBL] [Abstract][Full Text] [Related]
18. Mutant p53 in cancer therapy-the barrier or the path.
Zhou X; Hao Q; Lu H
J Mol Cell Biol; 2019 Apr; 11(4):293-305. PubMed ID: 30508182
[TBL] [Abstract][Full Text] [Related]
19. Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53.
Martinez-Rivera M; Siddik ZH
Biochem Pharmacol; 2012 Apr; 83(8):1049-62. PubMed ID: 22227014
[TBL] [Abstract][Full Text] [Related]
20. Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib.
Broxterman HJ; Gotink KJ; Verheul HM
Drug Resist Updat; 2009; 12(4-5):114-26. PubMed ID: 19648052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
